[0007a] In one aspect of the present disclosure, there is provided a compound represented by:



wherein

Y is $S(O)_y$ wherein y is 2;

R^Z is H;

$R^{m'}$ and R^m are each H;

L is a bond or C_{1-2}alkylene optionally substituted by halogen or C_{1-2}alkyl;

A is a 5-6 membered monocyclic heteroaryl ring optionally substituted by one or two substituents selected from the group consisting of halogen, hydroxyl, cyano, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, and NR'R'';

B is selected from the group consisting of phenyl optionally substituted by one, two or three substituents represented by R^{33}, 5-6 membered monocyclic heteroaryl optionally substituted by one, two or three substituents represented by R^{33}, and 9-10 membered bicyclic heteroaryl optionally substituted by one, two or three substituents represented by R^{33};

R' is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;

R'' is selected, independently for each occurrence, from H, methyl, ethyl, propyl, optionally substituted by hydroxyl, butyl optionally substituted by hydroxyl, –C(O)-methyl and –C(O)-ethyl, or R' and R'' taken together with the nitrogen to which they are attached may form a 4-7 membered heterocycle optionally substituted by one, two or more substituents selected from the group consisting of halogen, hydroxyl, NH_2, -C(O)-O-C_{1-3}alkyl, -C(O)-C_{1-3}alkyl, carboxy, oxo, and C_{1-3}alkyl;

each of moieties R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is independently selected for each occurrence from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkynyl, C_{2-6}alkenyl, halogen, hydroxyl, nitro, cyano, and NR'R'';

R^{33} is independently selected for each occurrence from the group consisting of halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, -CHO, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

q is 1, 2 or 3;

wherein for each occurrence, C_{1-6}alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R'' (where w is 0, 1 or 2); C_{1-6}alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R''(where w is 0, 1 or 2); and

pharmaceutically acceptable salts thereof.

[0007b] In another aspect of the present disclosure, there is provided a compound represented by:



;

and pharmaceutically acceptable salts thereof; wherein

Y is $S(O)_y$ wherein y is 2;

R^{33} is selected from the group consisting of halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, -CHO, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1, or 2), -$S(O)_w$-NR'R'' (where w is 0,1, or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

R' is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;

wherein for each occurrence, C_{1-6}alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, NR''R''', -NR''-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR''R''' (where w is 0, 1 or 2); C_{1-6}alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, NR''R''', -NR''-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR''R'''(where w is 0, 1 or 2).

[0007d] In another aspect of the present disclosure, there is provided a pharmaceutically acceptable composition comprising a compound disclosed herein, and a pharmaceutically acceptable excipient.

[0007e] In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein in the manufacture of a medicament for treating a hepatitis B infection.

[0007f] In another aspect of the present disclosure, there is provided a compound disclosed herein for use in treating a hepatitis B infection.

WHAT IS CLAIMED IS:

1. A compound represented by:



wherein

Y is $S(O)_y$ wherein y is 2;

R^Z is H;

$R^{m'}$ and R^m are each H;

L is a bond or C_{1-2}alkylene optionally substituted by halogen or C_{1-2}alkyl;

A is a 5-6 membered monocyclic heteroaryl ring optionally substituted by one or two substituents selected from the group consisting of halogen, hydroxyl, cyano, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, and NR'R'';

B is selected from the group consisting of phenyl optionally substituted by one, two or three substituents represented by R^{33}, 5-6 membered monocyclic heteroaryl optionally substituted by one, two or three substituents represented by R^{33}, and 9-10 membered bicyclic heteroaryl optionally substituted by one, two or three substituents represented by R^{33};

R' is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;

R'' is selected, independently for each occurrence, from H, methyl, ethyl, propyl, optionally substituted by hydroxyl, butyl optionally substituted by hydroxyl, –C(O)-methyl and –C(O)-ethyl, or R' and R'' taken together with the nitrogen to which they are attached may form a 4-7 membered heterocycle optionally substituted by one, two or more substituents selected from the group consisting of halogen, hydroxyl, NH_2, -C(O)-O-C_{1-3}alkyl, -C(O)-C_{1-3}alkyl, carboxy, oxo, and C_{1-3}alkyl;

each of moieties R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is independently selected for each occurrence from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkynyl, C_{2-6}alkenyl, halogen, hydroxyl, nitro, cyano, and NR'R'';

R^{33} is independently selected for each occurrence from the group consisting of halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-}

$_6$alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, -CHO, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

q is 1, 2 or 3;

wherein for each occurrence, C_{1-6}alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R'' (where w is 0, 1 or 2); C_{1-6}alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R''(where w is 0, 1 or 2); and

pharmaceutically acceptable salts thereof.

2. The compound of claim 1, wherein the compound is represented by:



.

3. The compound of claim 1 or 2, wherein A is a 5-6 membered monocyclic heteroaryl.

4. The compound of any one of claims 1-3, wherein A is pyridinyl.

5. The compound of any one of claims 1-3, wherein A is pyrimidinyl.

6. The compound of any one of claims 1-3, wherein A is thiadiazole.

7. The compound of any one of claims 1-6, wherein each of moieties R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is independently selected for each occurrence from the group consisting of hydrogen, methyl, trifluoromethyl, and halogen.

8. The compound of any one of claims 1-7, wherein each of moieties R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is hydrogen.

9. The compound of any one of claims 1-8, wherein A is optionally substituted by one substituent selected from the group consisting of halogen, C_{1-6}haloalkyl, and C_{1-6}alkyl.

10. The compound of any one of claims 1-9, wherein R^{33} is selected from the group consisting of halogen, hydroxyl, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', C_{1-6}alkoxy, carboxy, CHO, NR'R'', and -C_{1-6}alkyl-OH.

11. The compound of any one of claims 1-10, wherein L is a bond or a methylene.

12. The compound of any one of claims 1-11, wherein L is a bond.

13. The compound of any one of claims 1-12, wherein B is selected from the group consisting of indolyl, indazolyl, benzimidazolyl, and pyrimidinyl, each of which may be optionally substituted by one, two or three substituents represented by R^{33}.

14. The compound of any one of claims 1-13, wherein q is 1.

15. A compound represented by:



;

and pharmaceutically acceptable salts thereof; wherein

Y is $S(O)_y$ wherein y is 2;

R^{33} is selected from the group consisting of halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, -CHO, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1, or 2), -$S(O)_w$-NR'R'' (where w is 0,1, or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

R' is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;

R'' is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, –C(O)-methyl and –C(O)-ethyl, or R' and R'' taken together with the nitrogen to which they are attached may form a 4-7 membered heterocycle;

wherein for each occurrence, C_{1-6}alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R'' (where w is 0, 1 or 2); C_{1-6}alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R''(where w is 0, 1 or 2).

16. A compound represented by:



,



; and



and pharmaceutically acceptable salts thereof, wherein

R^{33} is selected from the group consisting of halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, -CHO, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0,1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

R^{43} is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, -CHO, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

R^{31} is optional, and may be selected from the group consisting of halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, -CHO, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-}

$_{6}$cycloalkyl, -S(O)$_w$-C$_{1-6}$alkyl (where w is 0, 1 or 2), -S(O)$_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-S(O)$_w$- C$_{1-6}$alkyl (where w is 0, 1 or 2); and

R^{44} is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, C$_{1-6}$alkyl, -C(O)-O-C$_{1-6}$alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C$_{2-6}$alkenyl, C$_{2-6}$alkynyl, C$_{1-6}$alkoxy, carboxy, -CHO, NR'R'', -C(O)-C$_{1-6}$alkyl, -C(O)-C$_{1-6}$alkoxy, C$_{3-6}$cycloalkyl, -S(O)$_w$-C$_{1-6}$alkyl (where w is 0, 1 or 2), -S(O)$_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-S(O)$_w$- C$_{1-6}$alkyl (where w is 0, 1 or 2); wherein for each occurrence, C$_{1-6}$alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C$_{2-6}$alkenyl, C$_{2-6}$alkynyl, C$_{1-6}$alkoxy, NR'R'', -NR'-S(O)$_w$- C$_{1-6}$alkyl (where w is 0, 1 or 2), and S(O)$_w$-NR'R'' (where w is 0, 1 or 2); C$_{1-6}$alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C$_{1-6}$alkyl, NR'R'', -NR'-S(O)$_w$- C$_{1-6}$alkyl (where w is 0, 1 or 2), and S(O)$_w$-NR'R''(where w is 0, 1 or 2);

R' is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;

R'' is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, –C(O)-methyl and –C(O)-ethyl, or R' and R'' taken together with the nitrogen to which they are attached may form a 4-7 membered heterocycle;

wherein for each occurrence, C$_{1-6}$alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C$_{2-6}$alkenyl, C$_{2-6}$alkynyl, C$_{1-6}$alkoxy, NR'R'', -NR'-S(O)$_w$- C$_{1-6}$alkyl (where w is 0, 1 or 2), and S(O)$_w$-NR'R'' (where w is 0, 1 or 2); C$_{1-6}$alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C$_{1-6}$alkyl, NR'R'', -NR'-S(O)$_w$- C$_{1-6}$alkyl (where w is 0, 1 or 2), and S(O)$_w$-NR'R''(where w is 0, 1 or 2).

17. A pharmaceutically acceptable composition comprising a compound of any one of claims 1-16, and a pharmaceutically acceptable excipient.

18. Use of a compound of any one of claims 1-16 in the manufacture of a medicament for treating a hepatitis B infection.

19. A compound of any one of claims 1-16 for use in treating a hepatitis B infection.